ArticleFrontiers in public health2025
Global burden and projections of breast cancer incidence and mortality to 2050: a comprehensive analysis of GLOBOCAN data.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effects of combined aerobic and resistance exercise on metabolic blood biomarkers and quality of life in patients with breast cancer: a systematic review meta-analysis.Frontiers in oncology · 2026Pooled it
- Willingness to contribute monetarily for hereditary breast cancer risk testing and the influencing factors: The first Indonesian exploration in the province with the highest prevalence.Exploratory research in clinical and social pharmacy · 2026Article
- Ellagic Acid and Metformin: In Vitro Synergy and Enhanced Cisplatin Efficacy In Vivo in Resistant Breast Cancer.Nutrients · 2026Article
- Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation.Molecular oncology · 2026Article
- In vitro study and in silico reveal Teucrium Polium L. methanolic extract as an apoptosis inducer and a potential Bcl-2 inhibitor for breast cancer.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- Cancer Treatment and Memory in Breast Cancer Survivors: Differential Effects on Detailed Episodic and Gist-Like Memory Recall Over Time.Hippocampus · 2026Article
- Automated breast ultrasound (ABUS) versus handheld ultrasound (HHUS) for the preoperative assessment of tumor size in invasive breast cancer.Journal of ultrasound · 2026Article
- Fear of Cancer Recurrence and Associated Factors Among Women with Female Cancer: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- CD6-Directed Immunotherapy Targets Breast Cancer Stem Cell Function and Enhances Immune-Mediated Cytotoxicity in Triple-Negative Breast Cancer.Biomolecules · 2026Article
- Design and Synthesis of Novel Morpholine-Derived Nitrogen-Rich Scaffolds as Multifunctional Anticancer and Antibacterial Agents: Biological Evaluation and Computational Studies.Pharmaceutics · 2026Article
- A Perspective on a Possible New Role for Bevacizumab Combined with Paclitaxel in Hormone-Resistant Metastatic Breast-Cancer Patients.Journal of clinical medicine · 2026Article
- Systems-Level Multi-Omics Analysis Resolves the Mechanism of Action of a Novel Multifunctional Nanosystem Against Triple-Negative Breast Cancer.Pharmaceutics · 2026Article
- Targeting CDK4/6 in Combination with Phage-Based Anti-HER2 Vaccination Overcomes Immune Evasion and Enhances the Anticancer Response in Breast Cancer.Pharmaceutics · 2026Article
- Special Issue: Toxicity of Metals, Metal-Based Drugs, and Microplastics.International journal of molecular sciences · 2026Article
- Ligand-Engineered Cu(II) Complexes Suppress Stemness and Drug Resistance in Triple-Negative Breast Cancer.ACS medicinal chemistry letters · 2026Article
- Recent Developments in Breast Cancer Diagnosis and Treatment.Medicina (Kaunas, Lithuania) · 2026Article
- Review
- Bioactive Profiling and Evaluation of Anti-Proliferative Potential ofLife (Basel, Switzerland) · 2026Article
- Temporal Patterns of Breast Cancer-Related Sickness Absence and Social Insurance Expenditures Among Women in Poland, 2020-2024: A Nationwide Registry-Based Study.Current oncology (Toronto, Ont.) · 2026Article
- Evaluating the Influence of Flaxseed Oil Against Docosahexaenoic Acid on Cancer Antigen CA15-3, Biochemical and Histopathological Parameters of DMBA-Induced Mammary Tumors Female Albino Wistar Rats.Food science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is a leading global health challenge, exhibiting significant regional disparities in incidence, mortality, and survival outcomes. This study analyzed the burden of breast cancer in 2022 and projects its future impact by 2050 using GLOBOCAN data. Methods: Incidence and mortality data for breast cancer from 2022 were analyzed across continents, age group, HDI and countries categories. The Average Annual Percent Change (AAPC) from 2018 to 2022 was calculated to project cases and deaths for 2050. Mortality-to-Incidence Ratios (MIR) were computed to assess survival disparities. Results: In 2022, Asia accounted for the highest breast cancer incidence (985,817 cases), followed by Europe (557,532) and Northern America (306,307). Africa recorded the highest mortality-to-incidence ratio (MIR) of 0.510, highlighting challenges in early detection and treatment. By 2050, global breast cancer cases are projected to exceed 6 million, with Asia, experiencing the most significant rise (2.0 million cases) followed by Africa (1.118 million cases), followed by. Mortality is expected to rise proportionally, with Asia (484,468) and Africa (390,695 deaths) and bearing the largest burden. The MIR for 2050 shows marked disparities, with Africa (0.35) and Asia (0.25) remaining elevated compared to Europe (0.20) and Northern America (0.13). Conclusion: The projected rise in breast cancer incidence and mortality highlights the urgent need for region-specific interventions. Targeted strategies focusing on early detection, improved access to treatment, and reduction of modifiable risk factors are essential, particularly in transitioning economies where disparities remain stark.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.